AIGH Capital Management LLC Has $5.83 Million Stock Position in PolyPid Ltd. $PYPD

Key Points

• AIGH Capital boosted its stake in PolyPid by 26.1% in Q4 to 1,342,972 shares (about 8.45% of the company) valued at $5.83 million, making it the fund's 21st largest holding, while institutional investors collectively own 26.47% of the stock.
• PolyPid trades around $4.44 with a market cap of $84.7M and a 52-week range of $2.44–$5.12, reported Q4 EPS of -$0.41 (missing estimates), and carries an analyst consensus of Moderate Buy with a $12.25 average price target.

AIGH Capital Management LLC boosted its position in PolyPid Ltd. (NASDAQ:PYPD - Free Report) by 26.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 1,342,972 shares of the company's stock after purchasing an additional 277,844 shares during the period. PolyPid comprises 1.4% of AIGH Capital Management LLC's holdings, making the stock its 21st largest position. AIGH Capital Management LLC owned about 8.45% of PolyPid worth $5,828,000 at the end of the most recent quarter.

Separately, BNP Paribas Financial Markets lifted its position in PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company's stock worth $32,000 after acquiring an additional 3,500 shares during the last quarter. Institutional investors own 26.47% of the company's stock.

PolyPid Stock Performance

Shares of PYPD opened at $4.44 on Friday. The stock has a 50 day moving average price of $4.36 and a two-hundred day moving average price of $4.17. The firm has a market capitalization of $84.72 million, a P/E ratio of -1.96 and a beta of 1.41. PolyPid Ltd. has a 52 week low of $2.44 and a 52 week high of $5.12.

PolyPid (NASDAQ:PYPD - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.07). On average, equities analysts forecast that PolyPid Ltd. will post -1.5 earnings per share for the current year.

Wall Street Analyst Weigh In

PYPD has been the subject of several research reports. Wall Street Zen upgraded shares of PolyPid from a "sell" rating to a "hold" rating in a research report on Saturday, March 14th. HC Wainwright restated a "buy" rating and set a $13.00 price objective on shares of PolyPid in a research report on Wednesday, February 11th. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, PolyPid currently has an average rating of "Moderate Buy" and a consensus price target of $12.25.

PolyPid Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.